Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 556 to 570 of 1688 results for carers

  1. Iclepertin for treating cognitive impairment associated with schizophrenia ID6483

    Awaiting development [GID-TA11647] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Baloxavir marboxil for Influenza

    Awaiting development [GID-TA11646] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Polyhexanide eye drops for treating acanthamoeba keratitis in people 12 years and over [ID6497]

    Awaiting development [GID-TA11643] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over ID6486

    Awaiting development [GID-TA11623] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Glycopyrronium bromide cream for treating severe primary axillary hyperhidrosis [TS ID 12050]

    Awaiting development [GID-TA11628] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. LY3209590 for treating type 1 diabetes in people on multiple daily insulin injections [ID6498]

    Awaiting development [GID-TA11645] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. LY3209590 for treating type 2 diabetes in people on daily insulin injections [ID6499]

    Awaiting development [GID-TA11644] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Obicetrapib or obicetrapib–ezetimibe for treating primary heterozygous hypercholesterolaemia or mixed dyslipidaemia TS ID 12103

    Awaiting development [GID-TA11649] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Finerenone for treating heart failure with preserved or mildly reduced ejection fraction TS ID 12051

    Awaiting development [GID-TA11651] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Durvalumab with tremelimumab and transarterial chemoembolisation with or without lenvatinib for treating locally advanced hepatocellular carcinoma TS ID 12117

    Awaiting development [GID-TA11653] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Atezolizumab for adjuvant treatment of circulating tumour DNA-positive high-risk muscle-invasive bladder cancer after cystectomy TS ID 12118

    Awaiting development [GID-TA11654] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy TS ID 12115

    Awaiting development [GID-TA11655] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Radium-223 dichloride with enzalutamide for treating asymptomatic or mildly symptomatic hormone-relapsed metastatic prostate cancer with bone metastases TS ID 12114

    Awaiting development [GID-TA11657] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment TS ID 12121

    Awaiting development [GID-TA11660] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Trastuzumab deruxtecan for adjuvant treatment of high-risk HER2-positive residual invasive breast cancer after neoadjuvant chemotherapy ID6509

    Awaiting development [GID-TA11658] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development